StockData
Maravai LifeSciences Holdings, Inc. logo

Maravai LifeSciences Holdings, Inc. (MRVI) stock

MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30170% above fair value
$7.28−0.12 (-1.62%)

Close on Nov 17, 2026Market cap $1.89BP/E –Yield –

Maravai LifeSciences profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Maravai LifeSciences's profit margin for the twelve months ending Jun 30, 2026 was -37.1%. For fiscal 2025 it was -70.4%, against -55.9% the year before. The highest annual figure on record is 31.3% in fiscal 2020.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-70.4%−14.5
FY2024Dec 31, 2024-55.9%−14.7
FY2023Dec 31, 2023-41.2%−66.1
FY2022Dec 31, 202224.9%+2.2
FY2021Dec 31, 202122.8%−8.5
FY2020Dec 31, 202031.3%+34.4
FY2019Dec 31, 2019-3.1%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-24.1%+59.4
Q1 FY2026Mar 31, 2026-5.7%+58.2
Q4 FY2025Dec 31, 2025-71.6%−25.8
Q3 FY2025Sep 30, 2025-61.4%+79.2
Q2 FY2025Jun 30, 2025-83.5%−69.4
Q1 FY2025Mar 31, 2025-63.9%−45.1
Q4 FY2024Dec 31, 2024-45.8%+97.1
Q3 FY2024Sep 30, 2024-140.6%−131.0
Q2 FY2024Jun 30, 2024-14.1%−4.6
Q1 FY2024Mar 31, 2024-18.8%−18.7
Q4 FY2023Dec 31, 2023-142.9%−161.3
Q3 FY2023Sep 30, 2023-9.7%−32.9
Q2 FY2023Jun 30, 2023-9.5%−38.8
Q1 FY2023Mar 31, 2023-0.1%−27.5
Q4 FY2022Dec 31, 202218.4%−6.1
Q3 FY2022Sep 30, 202223.3%−3.1
Q2 FY2022Jun 30, 202229.3%+6.8
Q1 FY2022Mar 31, 202227.4%+11.8
Q4 FY2021Dec 31, 202124.4%−1.2
Q3 FY2021Sep 30, 202126.3%−18.0
Q2 FY2021Jun 30, 202122.6%+19.5
Q1 FY2021Mar 31, 202115.6%−30.3
Q4 FY2020Dec 31, 202025.6%–
Q3 FY2020Sep 30, 202044.3%–
Q2 FY2020Jun 30, 20203.0%–
Q1 FY2020Mar 31, 202045.9%–

More Maravai LifeSciences figures

See a number that looks wrong?